ASCO 2026’s Most Consequential Lung Cancer Result: Ivonescimab Cuts Death Risk by 34% in Squamous NSCLC

A bispecific antibody engineered to block two immunosuppressive pathways at once became the first drug in history to beat a PD-1 inhibitor plus chemotherapy in advanced squamous lung cancer. The HARMONi-6 plenary result from ASCO 2026 may permanently shift how oncologists treat one of the most lethal malignancies on earth.

Presented By Our Partners

On the morning of May 31, 2026, the plenary hall at the American Society of Clinical Oncology annual meeting in Chicago fell unusually quiet as the final overall survival data from the HARMONi-6 trial appeared on the screen. The numbers were unambiguous: ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, extended median overall survival to 27.9 months in patients with advanced squamous non-small cell lung cancer. The comparator, tislelizumab combined with the same chemotherapy backbone, achieved 23.7 months. The difference, a 34 percent reduction in the risk of death, marked the first time any drug had beaten a PD-1 inhibitor plus chemotherapy in the first-line treatment of this historically difficult-to-treat cancer subtype.

The finding landed with the weight of a field-altering moment. Squamous NSCLC has sat in a therapeutic bind for years: largely bereft of the targetable mutations that made precision oncology so productive in other lung cancer subtypes, its patients have depended on the blunt force of immune checkpoint inhibitors and platinum-based chemotherapy. That standard of care, established through trials like KEYNOTE-407 in 2018, has remained essentially unchallenged for nearly a decade. HARMONi-6 ended that era.

Why Squamous NSCLC Has Been So Difficult to Treat

Non-small cell lung cancer accounts for approximately 85 percent of all lung cancer diagnoses, and squamous NSCLC makes up roughly 25 to 30 percent of that total. Unlike lung adenocarcinoma, which frequently harbors actionable driver mutations in genes like EGFR, ALK, ROS1, and KRAS, squamous NSCLC typically lacks these molecular handles. For most patients, the options have been immunotherapy, chemotherapy, or both.

Lung cancer kills roughly 125,000 Americans annually. Even with the immunotherapy revolution of the past decade, patients with stage IV squamous NSCLC have faced a median overall survival that rarely exceeds two years from first-line treatment. For those whose tumors express low levels of PD-L1, the benefit from checkpoint inhibitors is more modest, and the unmet need has been especially acute.

There is another layer of complexity specific to squamous disease: anti-VEGF therapy, which works in other NSCLC subtypes by cutting off the tumor’s blood supply, has historically been contraindicated in squamous lung cancer. The concern was hemorrhage, because squamous tumors are more centrally located and more closely associated with major blood vessels. That contraindication effectively closed off an entire therapeutic avenue for squamous patients. Ivonescimab’s design, it turns out, may have quietly solved that problem.

The Dual-Target Logic of Ivonescimab

Ivonescimab, developed by Akeso Inc. and licensed for Western markets to Summit Therapeutics, is not a conventional monoclonal antibody. It is a tetravalent, Fc-silent bispecific antibody that simultaneously engages two distinct immunosuppressive mechanisms in the tumor microenvironment: the PD-1/PD-L1 immune checkpoint axis and vascular endothelial growth factor, known as VEGF.

PD-1 blockade is by now a familiar concept. When a tumor overexpresses PD-L1, it essentially signals to T cells to stand down, cloaking the cancer from immune destruction. Antibodies that block PD-1 or PD-L1 lift that brake and allow cytotoxic T cells to resume their attack. That is the mechanism underlying pembrolizumab, nivolumab, and tislelizumab, the drugs ivonescimab was being compared against.

VEGF is less widely understood outside oncology, but its immunosuppressive function within tumors is well-established. Tumors secrete VEGF primarily to drive angiogenesis, the formation of new blood vessels that feed the growing mass. But VEGF does something equally damaging to the immune response: it recruits myeloid-derived suppressor cells and regulatory T cells into the tumor microenvironment, while simultaneously inhibiting the maturation of dendritic cells. The result is a profoundly immunosuppressive milieu that makes it harder for T cells to function even after PD-1 is unblocked.

Ivonescimab was engineered to address both problems simultaneously. Its structure is particularly elegant: an anti-PD-1 single-chain variable fragment is fused to each of the two heavy chains of an anti-VEGF antibody backbone, creating a four-armed molecule. In the tumor microenvironment, where VEGF concentrations are high, the antibody first binds VEGF dimers, forming larger multi-antibody complexes that then engage PD-1 on T-cell surfaces with significantly higher avidity. The molecule is, in effect, activated and concentrated by the very VEGF the tumor secretes.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Preclinical data published in Molecular Cancer Therapeutics had already suggested this cooperativity was real: the combination of PD-1 and VEGF blockade within a single molecule produced synergistic anti-tumor activity that exceeded what either target alone achieved. The HARMONi-6 data now provide the first large randomized Phase 3 confirmation of that biology in a squamous NSCLC population.

The HARMONi-6 Trial: Design and Results

HARMONi-6 enrolled 532 patients with pathologically confirmed squamous NSCLC at stage IIIB through IV who had not previously received systemic therapy for advanced disease. Patients were randomized to receive either ivonescimab plus platinum-based chemotherapy, or tislelizumab (Tevimbra, BeiGene) plus the same chemotherapy backbone. Tislelizumab was chosen as the comparator because it is a PD-1 inhibitor with an established efficacy profile in squamous NSCLC, providing a rigorous benchmark for the bispecific design.

After a median follow-up of 21.4 months, the results presented in Chicago were clear. The ivonescimab arm achieved a median overall survival of 27.9 months. The tislelizumab arm achieved 23.7 months. The hazard ratio, reflecting that 34 percent reduction in death risk, was statistically significant. The 4.2-month improvement in median OS may sound modest in isolation, but in a disease where every month represents meaningful time with family and the continuation of life, it is clinically consequential. Contextually, it represents an approximately 18 percent relative improvement in median OS over an already effective regimen.

Perhaps the most clinically important subgroup finding was the consistency of benefit across PD-L1 expression levels. For patients with PD-L1-negative tumors, the reduction in death risk was 36 percent. For PD-L1-positive patients, it was 32 percent. This is significant because PD-L1 negativity is typically associated with lower benefit from checkpoint inhibitors, yet ivonescimab’s VEGF-targeting component may be addressing a portion of the immunosuppression that PD-L1 status does not capture. For oncologists who have struggled to justify aggressive checkpoint inhibitor use in PD-L1-low or PD-L1-negative squamous patients, this data point offers a meaningful new tool.

On the safety front, the overall adverse event profile between the two arms was described as comparable. However, grade 3 or higher hemorrhagic events occurred in 2.6 percent of patients in the ivonescimab arm, compared with 0.8 percent in the tislelizumab arm. That signal warrants monitoring, even if rates were relatively low. It reflects the historical concern about VEGF blockade in squamous disease and suggests that patient selection and clinical vigilance will remain important as the drug moves into broader use.

The HARMONi Program in Context

HARMONi-6 does not exist in isolation. It is the latest in a series of large Phase 3 trials that have systematically tested ivonescimab across NSCLC subtypes. The earlier HARMONi-2 trial, published in The Lancet in 2024, had already demonstrated that ivonescimab significantly improved progression-free survival compared with pembrolizumab in patients with PD-L1-positive advanced NSCLC. That result, showing ivonescimab more than doubling progression-free survival versus the current global standard pembrolizumab, established the bispecific as a serious competitor in the most common biomarker-defined NSCLC population.

Ivonescimab has since received approval in China for multiple NSCLC indications. The U.S. Food and Drug Administration has accepted the Biologics License Application for ivonescimab in combination with chemotherapy for patients with EGFR-mutant NSCLC who have progressed on an EGFR tyrosine kinase inhibitor. The HARMONi-3 trial, which pits ivonescimab directly against pembrolizumab in first-line squamous NSCLC using a global patient population, is ongoing and designed to support FDA approval in that setting.

The ASCO 2026 plenary presentation carries particular historical weight. It was the first time a dataset from a China-alone clinical trial was selected for the ASCO plenary session, the meeting’s most prestigious scientific forum. That selection reflects not only the clinical magnitude of the result but also a broader shift in global oncology, where biotech companies from China are increasingly generating trial data that reset standards of care worldwide.

The Broader Significance for Oncology

The HARMONi-6 result joins a growing body of evidence suggesting that the future of cancer immunotherapy lies not in single-checkpoint blockade but in engineering drugs that address multiple immunosuppressive axes at once. VEGF has long been recognized as an immunosuppressive force within tumors, but early attempts to combine anti-VEGF therapy with checkpoint inhibitors in separate molecules produced toxicity challenges that limited their practicality, particularly in squamous disease.

Ivonescimab resolves this through engineering. By integrating both targets into a single molecule with a carefully calibrated structure, the drug appears to achieve VEGF blockade at concentrations and in a spatial context that produces meaningful immune activation without the systemic VEGF suppression that characterizes full-dose bevacizumab. The tetravalent format and the Fc-silent design, which reduces Fc receptor-mediated toxicity, are not incidental features. They are what make the drug work in a population where conventional anti-VEGF therapy has historically been off-limits.

The implications extend beyond squamous NSCLC. Akeso has ongoing trials of ivonescimab in non-squamous NSCLC, hepatocellular carcinoma, gastric cancer, and other solid tumors. The PD-1/VEGF bispecific platform appears broadly applicable wherever VEGF-driven immunosuppression contributes to treatment failure.

Several other bispecific antibodies in development share a conceptual lineage with ivonescimab’s approach. The success of this drug in a large randomized Phase 3 trial will almost certainly accelerate investment in multi-target checkpoint biologics across the industry. For patients with tumor types where immunotherapy has reached a plateau, this data offers a template for how to move past that ceiling.

Squamous NSCLC and the Longevity Framework

From the perspective of longevity medicine, lung cancer is one of what Healthcare Discovery identifies as the Four Shadows: the primary chronic disease threats to healthspan. Lung cancer remains the leading cause of cancer death in the United States, claiming more lives each year than breast, prostate, and colorectal cancers combined. Any result that extends median survival by months to years in a common and lethal subtype represents a meaningful addition to the armamentarium of treatments available to patients who are trying to bridge to the exponential improvements in medicine anticipated over the next decade.

The HARMONi-6 result also illustrates the accelerating convergence of molecular biology, drug engineering, and large-scale clinical validation that is beginning to reshape oncology. Understanding the tumor microenvironment as an ecosystem with multiple overlapping immunosuppressive signals, not just a single checkpoint, is producing drugs with qualitatively different efficacy. That conceptual shift, from single-target to multi-pathway intervention, will likely define the next generation of oncology breakthroughs.

What This Means For You

If you or someone close to you has been diagnosed with squamous non-small cell lung cancer, the HARMONi-6 result is genuinely significant news. While ivonescimab has not yet been approved by the FDA for squamous NSCLC in the United States, the trajectory toward approval is clear. The BLA for EGFR-mutant NSCLC is already under FDA review, and the HARMONi-3 global trial is designed specifically to generate the U.S.-eligible data needed for a squamous indication. Ask your oncologist specifically about ivonescimab and the HARMONi trials when discussing first-line treatment options.

For the broader population thinking about long-term health and longevity, this result reinforces several principles that sit at the core of cancer risk management. Squamous NSCLC is one of the lung cancer subtypes most strongly associated with tobacco smoking and chronic inflammation. The foundational practices of the Healthcare Discovery framework: optimizing nutrition to reduce systemic inflammation, prioritizing sleep and recovery, building cardiovascular fitness, and practicing breathwork to support vagal tone and stress physiology, all converge on reducing the inflammatory and oxidative conditions that create the soil in which these cancers grow. The best intervention remains prevention.

At the same time, for those already navigating a cancer diagnosis, results like HARMONi-6 represent precisely what longevity medicine’s bridge strategy is about: staying alive long enough to benefit from the next generation of treatments that are arriving at accelerating speed. Patients diagnosed with squamous NSCLC today have access to far better options than existed five years ago, and the drugs entering trials today will be far better still. In that context, every month of extended survival that ivonescimab provides is not just time. It is time with options.

The full HARMONi-6 dataset will likely be published in a major peer-reviewed journal in the coming weeks. As the data matures and FDA review progresses for the U.S. squamous indication, Healthcare Discovery will continue tracking ivonescimab’s path toward becoming the new standard of care.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.